About the vacancy
Drug Development
Infectious Diseases & Vaccines
About Your Next Job
In your role as Research Technician you will work on the development and implementation of assays for immunological characterization of therapeutic drug candidates across a range of different modalities. Your responsibilities will include day to day planning, execution and reporting of experiments to support the team. Our new colleague has a flexible mindset, appetite for learning new skills, conducts experiments efficiently, and is full of enthusiasm to join a lab within a fast-paced team of a highly dynamic company.
About Your Next Colleagues
You will join the Antibody Characterization and Optimization (ABCO) group within our Research department — a collaborative team of approximately 10 scientists and technicians dedicated to characterizing and advancing Leyden Labs’ novel therapeutic molecules. In this role, you will work closely with and under the supervision of a scientist within our Virus Neutralization Assay team. You will contribute to the development, optimization, and execution of virus neutralization assays to characterize innovative therapeutic candidates. The activities will be conducted at our Leyden Labs newly built, state of the art facilities within a vibrant campus in Leiden, Netherlands.
About Your Tasks and Responsibilities
- Perform experiments related to virus neutralization assays, including:
- Cell culture and cell banking
- propagation and stock generation
- Plaque assays and virus titration assays
- Virus neutralization assays - Prepare reagents, samples, and solutions for experimental work
- Collaborate with the team to develop and improve laboratory workflows
- Assist in the design, optimization, and troubleshooting of experimental protocols
- Maintain accurate and detailed records in electronic laboratory notebooks (eLNB)
About Your Skills and Experience
- Bachelor’s degree in Life sciences or related field
- Minimum of 2 years of laboratory experience (industry experience preferred, but not required)
- Proven experience with mammalian cell culture Hands-on experience working with viruses is a must and virus neutralization assays strongly preferred
- Experience working according to SOPs and laboratory guidelines, preferably in ML2/BSL2 environments
- Experience with additional techniques such as ELISA, SPR, or flow cytometry is a plus
- Proficiency in MS Office; experience with GraphPad Prism and eLNB systems is preferred
- Ability to quickly learn new techniques and adapt existing protocols to evolving research questions
- Strong written and verbal communication skills, including maintaining high-quality laboratory documentation
Where Molecules Meet Opportunities
- A challenging position (32-40 hours/week) in a dynamic start-up biotechnology company with high respect to a healthy work-life balance.
- International environment - collaboration with other labs and research institutes and more than 20 nationalities in the company.
- Contribute to the development of next generation medicines providing protection against airborne viruses
- A stimulating working environment with an enthusiastic team
- Attention and possibilities for personal and professional growth
- Competitive pay and benefits
Only apply if...
you have a Bachelor's degree with a minimum of 2 years of industry work experience or a Master's degree with max. 1-2 years of industry work experience. Master's gradudates without industry experience or PhD's will not be considered.
You are eligible to work in EU
We only accept applicants who are eligible to work in the EU
Contact person
Maisi Man
No video available
Leyden Labs is a Dutch biotechnology company employing a novel, non-vaccine approach to fight back against the threat of respiratory viruses. The goal is to provide unprecedented breadth of protection against respiratory viruses right in the palm of the hand of those who need protection the most. The company's product candidates are nasal sprays that are developed following the principles that they must provide protection right at the gate of viral entry (in the airway) and deliver superior breadth of protection. These product candidates offer an opportunity to overcome major limitations of existing vaccine-based protection.